Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma.
| Autor: | Landells FM; Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada., Goudie S; Division of Rheumatology, Memorial University of Newfoundland, St. John's, NL, Canada., McGrath J; Division of Gastroenterology, Memorial University of Newfoundland, St. John's, NL, Canada., Tibbo J; Division of Otolaryngology, Memorial University of Newfoundland, St. John's, NL, Canada., Landells ID; Division of Dermatology, Memorial University of Newfoundland, St. John's, NL, Canada. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | SAGE open medical case reports [SAGE Open Med Case Rep] 2023 Nov 16; Vol. 11, pp. 2050313X231213144. Date of Electronic Publication: 2023 Nov 16 (Print Publication: 2023). |
| DOI: | 10.1177/2050313X231213144 |
| Abstrakt: | Erosive lichen planus is a chronic auto-inflammatory disease which affects the stratified squamous epithelia resulting in painful ulcerations of both the skin and mucosal surfaces, and has a known malignant potential. Management of erosive lichen planus has proven to be difficult; however, recent reports of treatment with Janus kinase inhibitors such as Upadacitinib, are encouraging. This report outlines the third reported case of erosive lichen planus to be successfully treated with Upadacitinib in a 70-year-old woman with treatment-resistant disease. In addition, we report the complication of oral squamous cell carcinoma which became apparent once the extensive erosive lichen planus had healed. This case report highlights the importance of monitoring for mucosal squamous cell carcinoma in areas affected by erosive lichen planus, as squamous cell carcinoma can mimic the erosions of erosive lichen planus. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Declaration of Conflicting Interests for Dr. Ian Landells No other conflicts of interest to disclose. (© The Author(s) 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|